Sonic Healthcare Limited (SHL.AX)
- Previous Close
26.43 - Open
26.61 - Bid 26.51 x --
- Ask 26.54 x --
- Day's Range
26.32 - 26.63 - 52 Week Range
23.58 - 29.35 - Volume
920,495 - Avg. Volume
1,306,925 - Market Cap (intraday)
12.74B - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
23.26 - EPS (TTM)
1.14 - Earnings Date Feb 20, 2025
- Forward Dividend & Yield 1.07 (4.05%)
- Ex-Dividend Date Mar 5, 2025
- 1y Target Est
29.65
Sonic Healthcare Limited offers medical diagnostic and administrative services to medical practitioners, hospitals, community health services, and patients in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, general practice IT solutions, and community-based healthcare services. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.
www.sonichealthcare.com42,000
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: SHL.AX
View MorePerformance Overview: SHL.AX
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SHL.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SHL.AX
View MoreValuation Measures
Market Cap
12.70B
Enterprise Value
16.95B
Trailing P/E
23.22
Forward P/E
21.10
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.36
Price/Book (mrq)
1.55
Enterprise Value/Revenue
1.82
Enterprise Value/EBITDA
9.69
Financial Highlights
Profitability and Income Statement
Profit Margin
5.85%
Return on Assets (ttm)
4.01%
Return on Equity (ttm)
7.16%
Revenue (ttm)
9.33B
Net Income Avi to Common (ttm)
545.47M
Diluted EPS (ttm)
1.14
Balance Sheet and Cash Flow
Total Cash (mrq)
541.32M
Total Debt/Equity (mrq)
57.56%
Levered Free Cash Flow (ttm)
680.49M